Neuroprotective Compounds to Treat ParkinsonΓÇÖs Disease
- Orally bioavailable- Crosses the blood-brain barrier- Efficacy data in 3 animal models for ParkinsonΓÇÖs Disease- Accumulates in the substantia nigra and striatum within 1 hour, and persists for at least 24 hours- Protects dopaminergic neurons in vivo- Improved motor coordination (pole test, Rotor-Rod) and hyposmia (scent test)- No apparent long-term (12 months) side-effects or toxicity at therapeutically effective doses in a mouse model for PDIssued patents with broad composition of matter claims for Mito-apocynins and multiple derivative compounds, and method claims to:- Increase dopamine or dopac in the brain- Prevent a decrease in brain dopamine levels in Parkinson's disease- Reduce brain inflammation and/or neurotransmitter deficits- Delay neurodegeneration or lessen the effect of disease symptoms- Prolong motor function in a mammal with a neurodegenerative disease
Please view the complete technology summary and additional publications at "Technology page URL"
美国
